In consultation: Guidance and quality standards

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Consultation end date

Consultation end date

Type

Type

Guidance programme 5 selected

Guidance programme

Showing 1 to 10 of 10

TitleConsultationTypeConsultation end date
Pirtobrutinib for treating relapsed or refractory chronic lymphocytic leukaemia after a BTK inhibitor [ID6269]Draft guidanceTechnology appraisal guidance
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment [ID6474]Final draft guidanceTechnology appraisal guidance
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]Draft guidanceTechnology appraisal guidance
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]Draft guidanceTechnology appraisal guidance
Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Leriglitazone for treating cerebral adrenoleukodystrophy in boys and men 2 years and over [ID3903]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]Draft guidanceTechnology appraisal guidance
Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentatorsTechnology appraisal guidance
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441]Final draft guidanceTechnology appraisal guidance

Results per page

  1. 10
  2. 25
  3. 50
  4. All